


Supplementary Figure 1 the expression of LAMP1 and LAMP2 isoforms in bortezomib resistant MM cells. (A) Western blot analyses of the expression of LAMP1, LAMP2A, and LAMP2B in bone marrow samples from patients with MM (upper), and quantification of the bands (lower). (B) Western blot analyses of the expression of LAMP1, LAMP2A, and LAMP2B in U266 cells infected with PHLPP lentivirus under (upper), and quantification of the bands (lower). *P < 0.05.



Supplementary Figure 2 The effects of LAM2 on cell growth in U266-R and U266 cells. (A) Cell proliferation was evaluated using BrdU assay in U266-R cells that were infected with LAMP2 lentivirus and treated with 40 nM BTZ treatment. (B) Apoptosis was evaluated using flow cytometry in U266-R cells that were infected with LAMP2 lentivirus and treated with 40 nM BTZ treatment. (C) Cell proliferation was evaluated using BrdU assay in U266 cells that were infected with shLAMP2 lentivirus and treated with 5 nM BTZ treatment. (D) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment. (P) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment. (P) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment. (P) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment. (P) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment. (P) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment. (P) Apoptosis was evaluated using flow cytometry in U266 cells that were infected with 5 nM BTZ treatment.